Abstract
A new derivative ofL-asparaginase, palmitoyl-L-asparaginase (palmitoyl-L-ASNase), has been incorporated in liposomes. For this purpose we modified the dehydration-rehydration method and optimized the liposomal composition. The pharmacokinetics, toxicity, and in vivo antitumor activity against P1534 lymphoma of different liposomal palmitoyl-L-ASNase formulations were studied. Liposomal encapsulation of palmitoyl-L-ASNase as compared with free palmitoyl-L-ASNase resulted in a prolongation of the blood half-life (from 2.88 h to longer than 23.7 h), abrogation of acute toxicity, and preservation of in vivo antitumor activity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Allen TM, Chonn A (1987) Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223:42–46
Asselin BL, Ryan D, Frantz N, Bernal SD, Leavitt P, Sallan SE, Cohen HJ (1989) In vitro and in vivo killing of acute lymphoblastic leukemia cells byL-asparaginase. Cancer Res 49: 4363–4368
Broome JD (1981)L-Asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treat Rep 65 [Suppl 4]:111–114
Capizzi RL, Cheng Y-C (1981) Treatment of neoplasia with asparaginase. In: Holcenberg JC (ed) Enzymes as drugs. J. Wiley and Sons, New York Chicester Brisbane Toronto Singapore, pp 2–24
Capizzi RL, Handschumacher RE (1982) Asparaginase. In: Holland JF, Frei E III (eds) Cancer medicine. Lea and Febiger, Philadelphia, pp 920–933
Chang TMS (1971) The in vivo effect of semipermeable microcapsules containing L-Asparaginase on 6C3HED lymphosarcoma. Nature 229:117–118
Charles LM Jr, Bono VH Jr (1981) A review of the preclinical antitumor activity and toxicology ofL-asparaginase derived fromE. coli. Cancer Treat Rep 65 [Suppl 4]:39–46
Clarkson B, Krakoff I, Burchenal J, Karnofsky D, Golbey R, Dowling M, Oettgen H, Lipton A (1970) Clinical results of treatment withE. coli L-asparaginase in adults with leukemia, lymphoma and solid tumors. Cancer 25:279–305
Cruz ME, Corvo ML, Jorge JS, Lopes F (1989) Liposomes as carriers of proteins: factors affecting protein encapsulation. In: Lopez-Berenstein G, Fidler IJ (eds) Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, New York, pp 417–426
Cruz MEM, Gaspar MM, Lopes F, Jorge JS, Perez-Soler R (1993) LiposomalL-asparaginase: in vitro evaluation. Int J Pharm 96: 67–77
Dousset N, Douste-Balazy L (1985) Méthodes de préparation des liposomes. In: Puisieux F, Delattre J (eds) Les liposomes: applications thérapeutiques. Technique et Documentation-Lavoisier, Paris, pp 41–72
Fishman Y, Citri N (1975)L-Asparaginase entrapped in liposomes: preparation and properties. FEBS Lett 60:17–20
Fiske CH, Subbarow J (1925) The colorimetric determination of phosphorus. J Biol Chem 66:375–400
Gabizon A, Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85:6949–6953
Gregoriadis G, Leathwood PD, Ryman BE (1971) Enzyme entrapment in liposomes. FEBS Lett 14:95–99
Haskell CM (1981)L-Asparaginase: human toxicology and single agent activity in nonleukemic neoplasms. Cancer Treat Rep 65 [Suppl 4]:57–59
Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A, Newman RA, Krakoff IH (1986) Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 14:349–352
Jayaram HN, Cooney DA, Jayaram S, Rosenblum L (1974) A simple and rapid method for the estimation ofL-asparaginase in chromatographic and electrophoretic effluents: comparison with other methods. Anal Biochem 59:327–346
Juliano RL (1988) Factors affecting the clearance kinetics and tissue distribution of liposome, microspheres and emulsions. Adv Drug Deliv Rev 2:37–54
King EJ (1932) The colorimetric determination of phosphorus. Biochem J 26:292–297
Kirby C, Gregoriadis G (1984) Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology November: 979–984
Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams TE (1972) Toxicity ofL-asparaginase in children with advanced leukemia. Cancer 30:339–347
Lowry OH, Rosebrough NJ, Farr AL, Randall RT (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275
Martins MBF, Jorge JCS, Cruz MEM (1990) Acylation ofL-asparaginase with total retention of enzymatic activity Biochimie 72: 671–675
Mashburn LT, Wriston JC Jr (1964) Tumor inhibitory effect ofL-asparaginase fromEscherichia coli. Arch Biochem Biophys 105: 450–452
Mori T, Tosa T, Chibata I (1973) Enzymatic properties of microcapsules containing Asparaginase like also to include the last page number of this. Biochim Biophys Acta 321:653–661
Neerunjun ED, Gregoriadis G (1976) Tumour regression with liposome-entrapped asparaginase: some immunological advantages. Biochem Soc Trans 4:133–134
Oettgen HF, Stephenson PA, Schawartz MK, Leeper RD, Tallal L, Tan CC, Clarkson BD, Golbey RB, Krakoff IH, Karnofsky DA, Murphy ML, Burchenal JH (1970) Toxicity ofE. coli L-asparaginase in man. Cancer 25:253–278
Oshawa T, Miura H, Harada K (1985) Evaluation of a new lipsome technique, the freeze-thawing method, usingL-asparaginase as a model drug. Chem Pharm Bull (Tokyo) 33:2916–2923
Roberts J, Prager MD, Bachynsky N (1966) The antitumor activity ofEscherichia coli L-asparaginase. Cancer Res 26:2213–2217
Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Ito K, Matsuda T (1989) Changes in hemostatic and fibrinolytic proteins in patients receivingL-asparaginase therapy. Am J Hematol 32: 20–23
Wang C-H, Smith RL (1975) Lowry determination of the protein in the presence of Triton X-100. Anal Biochem 63:414–417
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jorge, J.C.S., Perez-Soler, R., Morais, J.G. et al. Liposomal palmitoyl-L-asparaginase: characterization and biological activity. Cancer Chemother. Pharmacol. 34, 230–234 (1994). https://doi.org/10.1007/BF00685082
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685082